New Product Applications
Harrow’s Iheezo, a topical ocular anesthetic, is the first FDA-approved use of chloroprocaine hydrochloride in the US ophthalmic market.
Harrow’s Iheezo, a topical ocular anesthetic, is the first FDA-approved use of chloroprocaine hydrochloride in the US ophthalmic market.
(5/14/24) The blood-retinal barrier is designed to protect our vision from infections by preventing microbial pathogens from reaching the retina where they could trigger an…
Compared to in-person medical conferences, video conferences come with a unique set of challenges, including video camera fatigue, lack of sustained engagement, concurrent multi-tasking, and…
Featuring six intricate case presentations and engaging seven expert panelists in invigorating discussions, this live, interactive, virtual event will act as a practical and pivotal…
Andrew Stewart of Bausch + Lomb discusses the company’s latest campaign, Faces of Glaucoma
A dilated eye exam is the only way to check for eye diseases early on, when they’re easier to treat. Learn more about dilated eye…
To evaluate safety and tolerability of EYP-1901, an intravitreal insert containing vorolanib, a pan–vascular endothelial growth factor (VEGF) receptor inhibitor packaged in a bioerodible delivery…
FORT LAUDERDALE, Fla. — Rare cases of occlusive retinal vasculitis have occurred with intravitreal therapies, and fluorescein angiography is an important tool to identify and…
Multidisciplinary collaboration between ophthalmology and optometry
May is Mental Health Month. Mental health and vision changes significantly impact blind or low vision person’s life.